Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal strong confidence in product efficacy and regulatory progress, particularly with DT120 for PTSD. The company is proactive in addressing study design issues and is engaged in strategic discussions with regulatory bodies. While some management responses were vague, the overall sentiment is optimistic, especially with plans for concurrent filings and supportive market dynamics. The positive sentiment is further bolstered by strategic partnerships and anticipated cash runway.
Key Financial Performance
Research and Development (R&D) Expenses $41.5 million for Q1 2026 compared to $23.4 million for Q1 2025, an increase of $18.1 million. The increase was primarily driven by $15.2 million in DT120 program expenses, $3.2 million in internal personnel costs due to expanding R&D capabilities, and $0.3 million in DT402 program expenses, partially offset by a $0.6 million reduction in preclinical and other program expenses.
General and Administrative (G&A) Expenses $17.7 million for Q1 2026 compared to $8.8 million for Q1 2025, an increase of $8.9 million. The increase was primarily due to $3.9 million in stock-based compensation expenses, $1.4 million in personnel-related expenses, $1.4 million in commercial preparedness expenses, $1.4 million in corporate and government affairs expenses, and $1.2 million in legal and patent expenses, partially offset by a $0.4 million reduction in other miscellaneous administrative expenses.
Net Loss $77.1 million for Q1 2026 compared to $23.3 million for Q1 2025. The increase was significantly impacted by a $20 million change in the fair value of 2022 USD financing warrants, reflecting an increase in share price from $13.39 at December 31, 2025, to $18.90 at March 31, 2026.
Cash, Cash Equivalents, and Investments $373.4 million as of the end of Q1 2026. This capital position is expected to fund planned operations through multiple anticipated clinical readouts and into 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DT120 ODT Phase III Trials: Advancing with 4 ongoing Phase III studies for major depressive disorder (MDD) and generalized anxiety disorder (GAD). Top-line data from Emerge expected later this quarter, followed by Voyage and Panorama in Q3 2026. Plans to expand into PTSD with the Haven study in 2027.
DT402 Phase II Trials: Developing DT402 for autism spectrum disorder (ASD) to address social communication challenges. Promising prosocial effects observed with favorable tolerability profile.
Market Opportunity for DT120: Targeting GAD and MDD markets with a focus on patients who have failed 2 or more treatments. Estimated $2 billion annual revenue opportunity by capturing 1% of the addressable market.
Commercial Strategy: Focused on high-volume psychiatrists and psychiatric nurse practitioners. Emphasis on scalable, accessible, and practical adoption in real-world care settings.
Financial Investments: R&D expenses increased to $41.5 million in Q1 2026, primarily driven by DT120 program expenses. G&A expenses rose to $17.7 million, reflecting investments in commercial preparedness and organizational growth.
Capital Position: Ended Q1 2026 with $373.4 million in cash, sufficient to fund operations through multiple clinical readouts and into 2028.
Regulatory Progress: Breakthrough therapy designation for DT120 in GAD. Constructive working relationship with FDA to expedite NDA submission upon positive pivotal data.
Expansion into New Indications: Plans to initiate Haven study for PTSD in 2027, leveraging DT120's potential across high unmet need areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Progress: The company acknowledges risks associated with the regulatory approval process and clinical progress of their product candidates, including potential delays or challenges in obtaining FDA approval for DT120 ODT.
Market Conditions: Changes in market conditions could adversely impact the company's operations and financial performance.
Research and Development Costs: Significant increases in R&D expenses, particularly for DT120 and DT402 programs, could strain financial resources if clinical outcomes do not meet expectations.
Commercialization Preparedness: High investments in commercial preparedness, including personnel and infrastructure, may not yield expected returns if DT120 fails to achieve market acceptance.
Financial Losses: The company reported a significant net loss of $77.1 million for Q1 2026, which could impact long-term financial sustainability if losses continue.
Stock Price Volatility: The company's net loss is significantly impacted by changes in the fair value of financing warrants, reflecting stock price volatility, which could affect investor confidence.
Clinical Trial Execution: Risks related to trial execution, including maintaining data quality, consistency, and managing dropout rates, could impact the success of Phase III trials for DT120.
Unmet Market Needs: While the company aims to address unmet needs in psychiatry, failure to demonstrate significant differentiation or efficacy of DT120 could limit its market potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical Data Readouts: Top-line data from the Phase III Emerge study in major depressive disorder (MDD) is expected later this quarter. Data from the Voyage and Panorama studies in generalized anxiety disorder (GAD) are anticipated in the third quarter of 2026.
Regulatory Progress: Definium plans to move towards an NDA submission for DT120 ODT, subject to positive pivotal data. The company has established a constructive working relationship with the FDA.
Pipeline Expansion: Development of DT120 ODT will expand into post-traumatic stress disorder (PTSD) with the initiation of the Haven study planned for 2027.
Market Opportunity: The company estimates a $2 billion annual revenue opportunity by capturing just 1% of the total addressable market for GAD and MDD, based on Spravato's average annual price.
Commercial Strategy: Definium plans to focus its launch efforts on high-volume healthcare practitioners managing patients with unmet needs in psychiatric care. The strategy includes a centralized hub support model and field support for scalable adoption.
Financial Guidance: The company has $373.4 million in cash, cash equivalents, and investments, providing sufficient runway to fund operations through multiple clinical readouts and into 2028.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's thoughts on the long-term safety and retreatment data needed for approval in MDD and anxiety?
A:The company feels comfortable with the completion of Part A and the data available at the time of filing. They have sufficient safety exposure for both single dose and longer periods. The studies are designed to characterize treatment patterns and ensure sufficient data for FDA and clinical community.
Q:How confident is the company that only one dosing session monitor will be needed in practice?
A:The company is confident that a single monitor should be sufficient in the real world. They have collected regulatory-grade data to support this and believe clinical discretion will ensure patient safety.
Q:Why did the company choose a head-to-head active versus placebo design for the PTSD Haven study instead of including a low 50-microgram dose arm?
A:The company believes head-to-head is the best way to establish efficacy. The low dose arms in other studies were used to confound understanding of treatment allocation, but for primary evidence of efficacy, head-to-head is preferred.
Q:What factors contribute to the shorter patient journey in Phase III compared to Phase II?
A:The use of an orally dissolving tablet for faster absorption and revised monitoring procedures based on Phase II learnings contribute to a shorter patient journey. Discussions with the FDA also influenced the reduction in monitoring time.
Q:How does the company address the high placebo response observed in Phase II GAD studies?
A:The high placebo response was attributed to the study design, including a high likelihood of receiving drug and the presence of lower dose arms. Phase III studies have a lower allocation ratio and offer open-label drug in Part B, which should reduce placebo response.
Q:What are the company's convictions regarding the dose used in the PTSD program?
A:The company is confident in the dose based on Phase II dose range finding studies and transitional PK work. They believe the dose is appropriate across overlapping conditions like GAD, MDD, and PTSD.
Q:What is the overlap between MDD and GAD, and does one condition present more challenges than the other?
A:MDD is episodic, while GAD is a constitutive background state. Historically, MDD has been easier to treat due to its episodic nature. The company is confident in both indications but notes that GAD may be less diagnosed due to a lack of novel treatments.
Q:What are the economic incentives for clinics to adopt DT120, and how many clinics would be needed to treat 100,000 patients per year?
A:Clinics are preparing for psychedelics by allocating space and judging market demand. The company is building a reimbursement strategy to support adoption. The exact number of clinics needed depends on market dynamics and capacity.
Q:What are the advantages of DT120 for PTSD compared to other psychedelics?
A:DT120 is well-tolerated, with a predictable and gentle onset and offset, making it suitable for patients with high levels of anxious arousal, such as those with PTSD.
Q:What is the company's filing strategy for GAD and MDD?
A:The company is considering filing both indications concurrently or sequentially, depending on the data and discussions with the FDA. They are confident in their position for filing DT120.
Q:How much data is needed from Part B of the studies to inform retreatment circumstances and payer conversations?
A:Part B data will inform retreatment intervals and patterns. The company already has substantial Part B data and will continue to aggregate it to support FDA discussions and payer conversations.
Q:What is the current capacity in the market for treating patients with psychedelics, and what expansion is needed?
A:The company believes current capacity is sufficient and that setting up treatment rooms is not a significant financial or logistical bottleneck. They expect capacity to grow over time as adoption increases.
Q:What are the company's thoughts on the DEA rescheduling process after Phase III data?
A:The company supports streamlining the process to shorten the timeline from FDA approval to patient access. They are engaged in discussions with FDA and DEA to explore opportunities for acceleration.
Q:What metrics or signals is the company looking for in the DT402 ASD program?
A:The company is using a combination of patient-reported outcomes, clinician and caregiver observations, and digital behavioral markers to assess efficacy in ASD.
Q:Why was a MADRS score of 20 chosen as the trigger for redosing in the MDD OLE study?
A:A score of 20 represents the threshold between mild and moderate illness, where functional deficits begin to appear. This aligns with clinical judgment and the level at which treatment is typically considered.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the exact number of clinics needed to treat 100,000 patients per year, the specific timeframe for market expansion, and the detailed economic incentives for clinics to adopt DT120. Additionally, they did not provide a clear estimate of how much time the DEA rescheduling process would realistically save or specific metrics for payer conversations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASD
Analyst Day
DT ODT
Emerge
GAD
III study
Investor Analyst
MDD
Phase III
Voyage Panorama
administration
adoption
analysis
anxiety
approach
care
change
difference
disorder
durability
improvement
increase
indication
launch
line
market
need
opportunity
participant
patient
placebo
point
program
rate
readout
risk
therapy
tolerability
treatment
trial
week
DFTX Transcript
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Positive5-9
The earnings call summary and Q&A session reveal strong confidence in product efficacy and regulatory progress, particularly with DT120 for PTSD. The company is proactive in addressing study design issues and is engaged in strategic discussions with regulatory bodies. While some management responses were vague, the overall sentiment is optimistic, especially with plans for concurrent filings and supportive market dynamics. The positive sentiment is further bolstered by strategic partnerships and anticipated cash runway.
Definium Therapeutics, Inc. (DFTX) Q4 2025 Earnings Call Transcript
Positive2-26
Despite concerns about regulatory progress and cash runway, the financial performance was strong, with significant revenue growth, increased net income, and improved operating margins. The absence of dividend or buyback programs was noted, but not detrimental. Overall, the financial metrics and optimistic outlook suggest a positive stock price movement.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
